NKT Cell Activation via CD1d Binding Motif Peptides
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccination strategies for infectious diseases and allergic conditions face limitations due to the inability to effectively recognize and eliminate intracellular pathogens and tumors, as well as the weak immunogenicity of antigens, leading to limited efficacy and variability in response among individuals.
Innovation Solution
Development of peptides or polypeptides modified with CD1d binding motifs that can be presented by the CD1d molecule to activate NKT cells, enhancing the immune response by increasing cytokine production and cytolytic activity against infected cells or tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional vaccination strategies are used, then antigens are presented to the immune system, but the immunogenicity is weak and the efficacy is limited due to preferential induction of antibodies rather than immune cell activation
Solution Approach 1:
The invention combines peptide or polypeptide antigens with lipid moieties to create composite structures that can be presented by CD1d molecules to NKT cells. This composite approach allows simultaneous engagement of both adaptive (T cell receptor) and innate (natural killer) immune systems, thereby enhancing overall immunogenicity and vaccination efficacy beyond what conventional protein-based vaccines achieve alone
2Reliability
If intracellular pathogens or tumors are present, then the immune system should recognize infected cells, but infected cells reduce surface expression of MHC molecules to escape recognition
Solution Approach 1:
The invention uses CD1d molecules as intermediary structures that present lipid-peptide complexes to NKT cells. This intermediary mechanism bypasses the MHC class I/II presentation pathway that pathogens exploit to escape detection, providing an alternative route for immune recognition that is not easily subverted by intracellular pathogens or tumors
3Adaptability or versatility
If there is diversity in MHC determinants, then individual immune responses vary, but this leads to significant variation in vaccination efficacy from one subject to another
Solution Approach 1:
The invention targets NKT cells through CD1d presentation of lipid-peptide complexes, which represents a more universal pathway compared to MHC-restricted T cell recognition. By engaging the invariant T cell receptor of NKT cells alongside the variable T cell receptor, this approach achieves broader cross-individual efficacy while maintaining the ability to adapt to different pathogen-specific antigens
Data Source
AI summary
The invention describes a method and compounds for the prevention and treatment of infections with intracellular organisms, the treatment of tumors, and the prevention of infectious and allergic diseases by vaccination.